Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20

Loss of CD20 is a major obstacle for the retreatment of relapsed/refractory diffuse large B cell lymphoma (DLBCL) with Rituximab-associated regimens. Histone deacetylation causes gene silencing and inhibits CD20 expression. Chidamide is a novel inhibitor for histone deacetylases (HDACs). We hypothes...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Xu-Wen, Wang, Hua-Qing, Ban, Wei-Wei, Chang, Zhi, Chen, Hai-Zhu, Jia, Li, Liu, Feng-Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944697/
https://www.ncbi.nlm.nih.gov/pubmed/31907371
http://dx.doi.org/10.1038/s41419-019-2210-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944697/
https://www.ncbi.nlm.nih.gov/pubmed/31907371
http://dx.doi.org/10.1038/s41419-019-2210-0

Ejemplares similares